Figure 5.

Cycloleucine decreases the m⁶A level and depresses myoblast cell proliferation. (A) RNA dot blot was used to detect the m⁶A modification after being treated with 0, 10, 20, and 30 mM cycloleucine for 24 h, methylene blue staining was used as a loading control (n = 3). (B) The relative gray value of RNA dot blot. (C) qRT-PCR results for CCNB1, CDK1, and CDK2 after treated with 0, 10, 20, and 30 mM cycloleucine for 24 h. (D) Distribution proportion of different cell stages after 24 h cycloleucine treatment. (E) The statistical results of CCK-8 assay after 24 h, 36 h, and 48 h cycloleucine treatment. (F and G) The EdU positive cell rate (F) and EdU staining (G) of myoblast cells being treated with cycloleucine. (*P < 0.05, **P < 0.01)